While few are watching, Spectral AI is building a future leader in burn care. This is a global market worth over $3.5 billion annually, with demand spanning the United States, Europe, and Australia. Their DeepView technology doesn’t just innovate. It outperforms human doctors in assessing burn wounds using more than 340 billion validated clinical data points.
Spectral AI is set to file its De Novo submission with the FDA by June 2025. This moment could be a major turning point. FDA acceptance would not only validate the science but also trigger significant media coverage. That attention could send the stock to $2.00 to $3.00 quickly, possibly within Q3 - Q4 2025.
Once approved, DeepView may become the new standard of care for burn treatment. Hospitals, trauma centers, and military contracts from around the world could start placing thousands of orders.
When DeepView officially commercialized, not to forget research grants and future contracts with the US Department of Defend.
MDAI to the moon 🚀, at least $5.00 next year.